Will Cascadian Therapeutics Inc (USA) (CASC) Short Squeeze Soon? The Stock Formed a Bearish Double Bottom Chart Pattern

July 26, 2017 - By Stephen Andrade

The chart of Cascadian Therapeutics Inc (USA) (CASC) shows a double bottom with $3.83 target or 4.00 % below today’s $3.99 share price. The 5 months chart pattern indicates high risk for the $197.92 million company. It was reported on Jul, 26 by Finviz.com. If the $3.83 price target is reached, the company will be worth $7.92 million less. Double bottoms are rare but powerful chart patterns.

The stock decreased 1.48% or $0.06 during the last trading session, reaching $3.99. About shares traded. Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) has declined 30.85% since July 26, 2016 and is downtrending. It has underperformed by 47.55% the S&P500.

Analysts await Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) to report earnings on August, 14. They expect $-0.25 EPS, up 30.56 % or $0.11 from last year’s $-0.36 per share. After $-0.30 actual EPS reported by Cascadian Therapeutics Inc (USA) for the previous quarter, Wall Street now forecasts -16.67 % EPS growth.

More notable recent Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) news were published by: Globenewswire.com which released: “Cascadian Therapeutics Announces Presentations of Updated Clinical Data at the …” on November 15, 2016, also Globenewswire.com with their article: “Cascadian Therapeutics Announces Stockholders and Board of Directors Approve …” published on November 23, 2016, Globenewswire.com published: “Cascadian Therapeutics Announces Changes to Board of Directors” on March 13, 2017. More interesting news about Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) were released by: Seekingalpha.com and their article: “Cascadian Therapeutics’ (CASC) CEO Scott Myers on Q1 2017 Results – Earnings …” published on May 09, 2017 as well as Globenewswire.com‘s news article titled: “Cascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in …” with publication date: December 07, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.